获取 COVID-19 疫苗。
Access to the COVID-19 Vaccine.
机构信息
Laboratory for Health Technology Assessment, Department of Public Health Policy, School of Public Health, University of West Attica, 11521 Athens, Greece.
出版信息
Int J Environ Res Public Health. 2022 Sep 3;19(17):11054. doi: 10.3390/ijerph191711054.
Abstract
As of 31 August 2022, 599,825,400 confirmed coronavirus disease 2019 (COVID-19) cases and 6,469,458 deaths have been reported globally [...].
摘要
截至 2022 年 8 月 31 日，全球已报告 599825400 例确诊的 2019 年冠状病毒病（COVID-19）病例和 6469458 例死亡[... ]。
相似文献
1
Access to the COVID-19 Vaccine.获取 COVID-19 疫苗。
Int J Environ Res Public Health. 2022 Sep 3;19(17):11054. doi: 10.3390/ijerph191711054.
2
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
3
SARS-CoV-2 vaccine candidates in rapid development.正在快速开发的 SARS-CoV-2 疫苗候选物。
Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.
4
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19（Sars-Cov-2）的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
5
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
6
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
7
Safety of mRNA-Based Vaccines for SARS CoV-2.mRNA 疫苗在 SARS-CoV-2 中的安全性。
Chem Res Toxicol. 2021 Aug 16;34(8):1823-1825. doi: 10.1021/acs.chemrestox.1c00129. Epub 2021 May 19.
8
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗：辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
9
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
10
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
引用本文的文献
1
Ensuring Equitable Access to the COVID-19 Vaccine: The Experience of A Local Health Unit in Rome, Italy.确保公平获得新冠疫苗：意大利罗马一个地方卫生单位的经验
Healthcare (Basel). 2022 Nov 10;10(11):2246. doi: 10.3390/healthcare10112246.
本文引用的文献
1
COVID-19 Vaccine Challenges in Developing and Developed Countries.发展中国家和发达国家的新冠疫苗挑战
Cureus. 2022 Apr 8;14(4):e23951. doi: 10.7759/cureus.23951. eCollection 2022 Apr.
2
A qualitative study of COVID-19 vaccine intentions and mistrust in Black Americans: Recommendations for vaccine dissemination and uptake.一项关于美国黑人对 COVID-19 疫苗接种意愿和不信任的定性研究：疫苗传播和接种建议。
PLoS One. 2022 May 3;17(5):e0268020. doi: 10.1371/journal.pone.0268020. eCollection 2022.
3
Barriers to COVID-19 Vaccines and Strategies to Improve Acceptability and Uptake.新冠病毒疫苗接种障碍及提高可接受性和接种率的策略。
J Pharm Pract. 2023 Aug;36(4):900-904. doi: 10.1177/08971900221081621. Epub 2022 Apr 23.
4
Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.全球 COVID-19 疫苗政策、覆盖范围和需求的多样性：描述性研究。
BMC Med. 2022 Apr 4;20(1):130. doi: 10.1186/s12916-022-02333-0.
5
Melatonin use for SARS-CoV-2 infection: Time to diversify the treatment portfolio.褪黑素用于新型冠状病毒感染：是时候使治疗方案多样化了。
J Med Virol. 2022 Jul;94(7):2928-2930. doi: 10.1002/jmv.27740. Epub 2022 Apr 12.
6
It is not too late to achieve global covid-19 vaccine equity.实现全球新冠疫苗公平分配还为时不晚。
BMJ. 2022 Mar 24;376:e070650. doi: 10.1136/bmj-2022-070650.
7
Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.应对疫苗不平等——将新冠疫苗视为全球公共产品
N Engl J Med. 2022 Mar 24;386(12):1176-1179. doi: 10.1056/NEJMe2202547. Epub 2022 Feb 23.
8
Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.在加强针接种之际纠正 COVID-19 疫苗不平等现象：为全球卫生团结绘制大胆路线，共同努力。
Global Health. 2022 Feb 22;18(1):23. doi: 10.1186/s12992-022-00817-5.
9
Global discrimination of COVID-19 vaccine.全球新冠疫苗的歧视。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2028515. doi: 10.1080/21645515.2022.2028515. Epub 2022 Feb 17.
10
Equitable access to COVID-19 vaccines makes a life-saving difference to all countries.公平获取 COVID-19 疫苗对所有国家都有着生死攸关的意义。
Nat Hum Behav. 2022 Feb;6(2):207-216. doi: 10.1038/s41562-022-01289-8. Epub 2022 Jan 31.
Zotero 插件